MyHealtheVet PHR FHIR API
0.3.9-current - ci-build United States of America flag

MyHealtheVet PHR FHIR API, published by VA Digital Services. This guide is not an authorized publication; it is the continuous build for version 0.3.9-current built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/department-of-veterans-affairs/mhv-fhir-phr-mapping/ and changes regularly. See the Directory of published versions

Example DocumentReference: Note 6

Page standards status: Informative

This is a sample of a note that was signed, and for which an addenda is added and signed. This is the update of note-5, note only the body text changes.

Derived from the following mock NoteTO:

<noteTO>
    <id>5298388</id>
    <timestamp>3231116.144</timestamp>
    <localTitle>STAGING (TNM) URINARY BLADDER</localTitle>
    <author>
        <id>36556</id>
        <name>AHMED,MARUF</name>
    </author>
    <location>
        <id>984ZZI</id>
        <name>ZZDAYTSHR</name>
    </location>
    <text>LOCAL TITLE: STAGING (TNM) URINARY BLADDER                      
DATE OF NOTE: NOV 16, 2023@14:40     ENTRY DATE: NOV 16, 2023@14:40:47      
      AUTHOR: AHMED,MARUF          EXP COSIGNER:                           
     URGENCY:                            STATUS: COMPLETED                     

   *** STAGING (TNM) URINARY BLADDER Has ADDENDA ***

URINARY BLADDER
6th edition AJCC Cancer Staging Manual


testing note with kbst team
 
CLIN   PATH     PRIMARY TUMOR (T)
 [X]   [ ]   TX      Primary tumor cannot be assessed
 [ ]   [ ]   T0      No evidence of primary tumor
 [ ]   [ ]   Ta      Non invasive papillary carcinoma
 [ ]   [ ]   Tis     Carcinoma in situ (flat tumor)
 [X]   [ ]   T1      Tumor invades subepithelial connective tissue
 [ ]   [ ]   T2      Tumor invades muscle
 [ ]   [ ]           T2a     Tumor Invades superficial (inner half)
 [ ]   [ ]           T2b     Tumor Invades deep muscle (outer half)
 [ ]   [X]   T3      Tumor invades perivesical tissue
 [ ]   [X]           T3a     Microscopically
 [ ]   [ ]           T3b     Macroscopically (extravesical mass)
 [ ]   [ ]   T4      Tumor invades any of the following: prostate,
                       uterus, vagina, pelvic or abdominal wall
 [ ]   [ ]           T4a     Tumor invades prostate, uterus, vagina
 [X]   [X]           T4b     Tumor invades pelvic wall, abdominal wall
 
 
               REGIONAL LYMPH NODES (N)
 [ ]   [ ]   NX      Regional lymph node metastasis cannot be assessed
 [ ]   [ ]   N0      No regional lymph node metastasis
 [ ]   [X]   N1      Mets in a single lymph node, 2 cm or less in
                       greatest dimension.
 [ ]   [X]   N2      Mets in a single lymph node more than 2 but not
                       more than 5 cm in greatest dimension; multiple
                       lymph nodes, none more than 5 cm in greatest
                       dimension.
 [ ]   [ ]   N3      Metastasis in a lymph node more than 5 cm
 
               DISTANT METASTASIS (M)
 [ ]   [X]   MX      Presence of distant metastasis cannot be assessed
 [ ]   [X]   M0      No distant metastasis
 [ ]   [ ]   M1      Distant metastasis
 
STAGE GROUPING
 [ ]   [ ]   Oa      Ta      N0      M0
 [ ]   [ ]   Ois     Tis     N0      M0
 [ ]   [ ]   I       T1      N0      M0
 [ ]   [X]   II      T2a     N0      M0
 [ ]   [ ]           T2b     N0      M0
 [ ]   [ ]   III     T3a     N0      M0
 [ ]   [X]           T3b     N0      M0
 [ ]   [ ]           T4a     N0      M0
 [ ]   [ ]   IV      T4b     N0      M0
 [X]   [ ]           Any T   N1      M0
 [X]   [ ]           Any T   N2      M0
 [X]   [ ]           Any T   N3      M0
 [X]   [ ]           Any T   Any N   M1
 
                       GRADE
        [ ]   GX      Grade cannot be assessed
        [X]   G1      Well differentiated
        [X]   G2      Mod differentiated
        [ ]   G3      Poorly differentiated
        [ ]   G4      Undifferentiated
 
 
OP #598c (552) Approved 12/99 Rev 03/03
 
/es/ MARUF AHMED
PHYSICIAN
Signed: 11/16/2023 14:50

11/16/2023 ADDENDUM                      STATUS: COMPLETED
Addendum test with KBST team 
 
/es/ MARUF AHMED
PHYSICIAN
Signed: 11/16/2023 14:57</text>
    <approvedBy>
        <id>36556</id>
        <name>AHMED,MARUF</name>
        <signature>MARUF AHMED PHYSICIAN</signature>
    </approvedBy>
    <status>completed</status>
    <type>PN</type>
    <procTimestamp>3231116.145026</procTimestamp>
</noteTO>

Generated Narrative: DocumentReference ex-MHV-note-6

identifier: urn:oid:2.16.840.1.113883.4.349.4.989/NoteTO.5298388 (use: usual, )

status: Current

type: Progress note

category: Clinical Note

subject: MTPZEROTWO DAYTSHR Male, DoB: 1000-01-01 ( urn:oid:2.16.840.1.113883.4.349#1 (use: usual, ))

date: 2023-11-16 14:40:00+0000

author: Practitioner AHMED,MARUF

authenticator: Practitioner AHMED,MARUF

content

Attachments

-ContentTypeDataTitle
*text/plain(base64 data - 4,216 base64 chars)STAGING (TNM) URINARY BLADDER

Contexts

-Related
*Location DAYTSHR TEST LAB

Generated Narrative: Practitioner #ex-MHV-practitioner-36556

identifier: urn:oid:2.16.840.1.113883.4.349.4.989/AuthorTO.37556 (use: usual, )

name: AHMED,MARUF


Generated Narrative: Location #ex-MHV-location-984

identifier: urn:oid:2.16.840.1.113883.4.349.4.989/HospitalLocationTO.984 (use: usual, )

name: DAYTSHR TEST LAB